CAR-T

Pfizer signs deal with Allogene to develop cancer cell therapy
Pfizer signs deal with Allogene to develop cancer cell therapy
Yahoo/Reuters
Pfizer
Allogene
CAR-T
drug development
Flag link:
Celgene, bluebird revise deal to co-develop CAR-T therapy
Celgene, bluebird revise deal to co-develop CAR-T therapy
Biopharma Dive
Celgene
Bluebird Bio
drug development
CAR-T
bb2121
Multiple Myeloma
Flag link:
Treatment Debates Won’t Slow Down Biotechs
Treatment Debates Won’t Slow Down Biotechs
Barron's
biotech
Gilead Sciences
CAR-T
Juno Therapeutics
Bellicum
Flag link:
Continuing Cell Therapy Push, Gilead Aligns with Sangamo for CAR-T Boost
Continuing Cell Therapy Push, Gilead Aligns with Sangamo for CAR-T Boost
Xconomy
cell therapy
Gilead Sciences
Sangama
CAR-T
gene editing
Flag link:
ICER declares costs of approved CAR-T therapies aligned with clinical benefit
ICER declares costs of approved CAR-T therapies aligned with clinical benefit
BioWorld
CAR-T
ICER
Gilead Sciences
Yescarta
Novartis
Kymriah
drug pricing
Flag link:
How Celgene Hopes to Cash In on CAR-T
How Celgene Hopes to Cash In on CAR-T
Yahoo/Motley Fool
Celgene
CAR-T
JCAR017
bb2121
Bluebird Bio
Flag link:
As CAR-Ts go from candidates to brands, what's the marketing strategy?
As CAR-Ts go from candidates to brands, what's the marketing strategy?
Medical Marketing and Media
CAR-T
drug marketing
JCAR017
Juno Therapeutics
Celgene
bb2121
Bluebird Bio
apalutamide
Janssen
Flag link:
Novartis move signals further gene therapy resurgence
Novartis move signals further gene therapy resurgence
EP Vantage
Novartis
gene therapy
Spark Therapeutics
CAR-T
Luxturna
Flag link:
Bluebird Bio Shouldn’t Be Blue About Celgene’s Juno Deal
Bluebird Bio Shouldn’t Be Blue About Celgene’s Juno Deal
Washington Post, DC
Bluebird Bio
Celgene
Juno Therapeutics
M&A
CAR-T
Flag link:
What to Expect From Amgen, Inc. in 2018
What to Expect From Amgen, Inc. in 2018
Motley Fool
Amgen
Enbrel
Neulasta
Aranesp
Epogen
Neupogen
Prolia
Repatha
CAR-T
Flag link:
Beefing up its CAR-T pipeline, Gilead teams up with Pfizer on a lymphoma combo
Beefing up its CAR-T pipeline, Gilead teams up with Pfizer on a lymphoma combo
Endpoints
CAR-T
Gilead Sciences
Pfizer
utomilumab
Yescarta
large B-cell lymphoma
Flag link:
Celgene is reportedly in talks to buy Juno Therapeutics
Celgene is reportedly in talks to buy Juno Therapeutics
CNBC
Celgene
Juno Therapeutics
M&A
CAR-T
Flag link:
Vantage view – Payers OK with CAR-T? Not so fast
Vantage view – Payers OK with CAR-T? Not so fast
EP Vantage
CAR-T
payers
ICER
Flag link:
J&J wows with a $350M cash deal to partner on CAR-T with Legend, a one-time unknown until its star turn at ASCO
J&J wows with a $350M cash deal to partner on CAR-T with Legend, a one-time unknown until its star turn at ASCO
Endpoints
JNJ
CAR-T
Legend Biotech
LCAR-B38M
BCMA
China
Flag link:
Juno inks CAR-T supply deal with Thermo Fisher
Juno inks CAR-T supply deal with Thermo Fisher
BioPharma Dive
Juno Therapeutics
Thermo Fisher
CAR-T
Flag link:
Kymriah, Yescarta found ‘cost-effective’ in treating cancer, despite high price
Kymriah, Yescarta found ‘cost-effective’ in treating cancer, despite high price
Endpoints
Kymriah
Yescarta
CAR-T
Novartis
Kite Pharma
Gilead Sciences
drug pricing
Flag link:
Celgene Shareholders Excited by CAR-T News
Celgene Shareholders Excited by CAR-T News
Motley Fool
Celgene
CAR-T
Bluebird Bio
bb2121
Flag link:
Is Gilead’s new CAR-T overpriced or is payer bureaucracy to blame for slow pickup?
Is Gilead’s new CAR-T overpriced or is payer bureaucracy to blame for slow pickup?
Fierce Pharma
Gilead Sciences
CAR-T
drug pricing
Yescarta
Flag link:
ASH 2017: CAR-T Wallops Blood Cancer
ASH 2017: CAR-T Wallops Blood Cancer
Motley Fool
ASH2017
CAR-T
gene therapy
Novartis
Kymriah
Yescarta
Gilead Sciences
Juno Therapeutics
JCAR017
Flag link:
bluebird bio Stock Soars on Unprecedented Blood Cancer Study Results
bluebird bio Stock Soars on Unprecedented Blood Cancer Study Results
Motley Fool
Bluebird Bio
bb2121
CAR-T
Celgene
Multiple Myeloma
ASH17
Flag link:

Pages